BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35680788)

  • 1. [Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations].
    Xia PH; Xu ZJ; Jin Y; Ma JC; Wen XM; Yuan Q; Leng JY; Qian J; Lin J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):659-670. PubMed ID: 35680788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALOX5AP is a new prognostic indicator in acute myeloid leukemia.
    Chen XY; Wen XM; Zhao W; Chu MQ; Gu Y; Huang HH; Yuan Q; Xu ZJ; Qian J; Lin J
    Discov Oncol; 2023 Nov; 14(1):210. PubMed ID: 37994961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Bai H; Zhou M; Zeng M; Han L
    DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid sarcoma with
    Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
    Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TG-interacting factor 1 improves risk stratification in patients with NPM1-mutated acute myeloid leukemia.
    Tang H; Zhang N; Li H; Chen Y; Liu X; Xiao H; Deng J; Zhou K
    Adv Clin Exp Med; 2023 Jul; 32(7):741-751. PubMed ID: 36753372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non‑coding RNA ANRIL is a potential indicator of disease progression and poor prognosis in acute myeloid leukemia.
    Tan Z; Zhu K; Yin Y; Luo Z
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NPM1 High Mutant Allele Burden is an Adverse Prognostic Factor for AML Patients with Mutated NPM1].
    Hou JX; Wang SJ; Liu YF; Hao QQ; Wang C; Li T; Bai JJ; Liao LX; Guo CY; Chang YY; Wang M; Sun H; Xie XS; Jiang ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):365-372. PubMed ID: 30998139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia.
    Xu Q; Guo T
    Hematology; 2022 Dec; 27(1):659-671. PubMed ID: 35666642
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic relevance of combined IDH1 and NPM1 mutations in the intermediate cytogenetic de novo acute myeloid leukemia.
    Abd El-Lateef AE; Ismail MM; Almohammadi M; Gawaly AM
    Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):92-98. PubMed ID: 34933728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleophosmin mutation in de-novo acute myeloid leukemia.
    Rastogi P; Naseem S; Varma N; Varma S
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
    Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
    Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
    Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.